- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00027976
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent actinic keratoses.
PURPOSE: Randomized phase II/III trial to determine the effectiveness of celecoxib in preventing skin cancer in patients who have actinic keratoses.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
- Compare celecoxib vs placebo in terms of preventing the development of new actinic keratoses in patients with actinic keratoses.
- Compare these treatment regimens in terms of inducing regression of actinic keratoses in these patients.
- Determine the safety of this drug in these patients.
- Compare the effect of these treatment regimens on potential surrogate end-point biomarkers in areas of actinic keratosis, sun-exposed skin, and non-sun-exposed skin and correlate these biomarkers with clinical outcome in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral celecoxib twice daily for 9 months in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo as in arm I. Patients are followed at 2 months after completing treatment.
PROJECTED ACCRUAL: A total of 240 patients (120 per treatment arm) will be accrued for this study.
Undersøgelsestype
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
California
-
Irvine, California, Forenede Stater, 92697
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109-0314
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Diagnosis of Fitzpatrick skin types I, II, or III
- Sun-damaged skin with 10-40 actinic keratoses on the upper extremities (upper arms, forearms, and hands), neck, face, and scalp combined
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count at least 125,000/mm^3
- Hemoglobin at least lower limit of normal
- No significant bleeding disorder
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST and ALT no greater than 1.5 times ULN
- No chronic or acute hepatic disorder
Renal:
- Creatinine no greater than 1.5 times ULN
- BUN no greater than 1.5 times ULN
- No chronic or acute renal disorder
Gastrointestinal:
- No history of or active inflammatory bowel disease
- No active pancreatitis
- Not diagnosed with esophageal, gastric, pyloric channel, or duodenal ulceration within the past 30 days
Other:
- No history of keloid formation
- No known photosensitivity disorder
- No history of hypersensitivity or adverse reaction to sulfonamides, COX-2 inhibitors, salicylates, or other NSAIDs
- No other condition that would preclude study
- No other medical or psychosocial condition that would preclude study
No other malignancy within the past 5 years except:
- Carcinoma in situ of the cervix
- Curatively excised nonmelanoma skin cancer
- Stage 0 chronic lymphocytic leukemia
- Any cancer for which the patient is currently without evidence of disease, has not been treated for tumor within the past 6 months, has no current or planned therapy, and has an expected disease-free survival of at least 5 years
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 30 days since prior systemic immunotherapy
- No concurrent immunotherapy
Chemotherapy:
- At least 3 months since prior topical fluorouracil (5-FU)
- At least 6 months since other prior topical chemotherapy
- No concurrent topical chemotherapy, including 5-FU
- No other concurrent chemotherapy
Endocrine therapy:
- At least 6 months since prior oral or IV corticosteroids for more than 2 consecutive weeks
- At least 6 months since prior inhaled or nasal corticosteroids for more than 4 weeks duration
- At least 14 days since prior topical corticosteroids
- At least 30 days since prior nasal corticosteroids (except mometasone)
- No concurrent oral or IV corticosteroids for more than 2 consecutive weeks during any 6 month period during study
- No concurrent inhaled or nasal steroids (except mometasone) for more than 4 weeks during any 6 month period during study
- No concurrent hormonal or steroidal therapy, including topical corticosteroids
- Concurrent hormone replacement therapy (e.g., estrogen or thyroid hormone replacement) allowed
Radiotherapy:
- At least 6 months since prior local radiotherapy to areas being studied
- At least 30 days since other prior radiotherapy
- No concurrent radiotherapy, including local radiotherapy to areas being studied
Surgery:
- Not specified
Other:
- At least 30 days since prior cryotherapy to target lesions
- At least 60 days since prior laser resurfacing, dermabrasion, or chemical peels
- At least 30 days since prior investigational medication
- At least 14 days since prior topical alphahydroxyacids (e.g., glycolic acid or lactic acid) or retinoids
- At least 30 days since prior systemic psoralens or retinoids
- At least 30 days since prior treatment for esophageal, gastric, pyloric channel, or duodenal ulcers
- At least 30 days since prior aspirin (more than 100 mg/day), other nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors at a frequency of at least 3 times per week for more than 2 weeks (except cardioprotective doses of aspirin (no more than 100 mg/day)
- No concurrent systemic psoralens or retinoids
- No concurrent prescription or over-the-counter topical medications to areas being studied (e.g., vitamin A derivatives)
- No concurrent cryotherapy to target lesions
- No concurrent laser resurfacing, dermabrasion, or chemical peels
- No other concurrent investigational medications
- No concurrent fluconazole or lithium
- No concurrent chronic NSAIDs or COX-2 inhibitors (at least 3 times per week for more than 2 consecutive weeks per year)
- Concurrent cardioprotective doses of oral aspirin (100 mg per day or less) allowed
- Concurrent moisturizer/emollient or sunscreen allowed
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Group 1 active arm
receipt of active drug
|
|
Eksperimentel: Group 2 active arm
receipt of active drug
|
|
Eksperimentel: group 2 placebo arm
receipt of placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Compare celecoxib vs placebo in terms of preventing the development of new actinic keratoses in patients with actinic keratoses.
Tidsramme: baseline to 2 months after last dose
|
baseline to 2 months after last dose
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Compare these treatment regimens in terms of inducing regression of actinic keratoses in these patients.
Tidsramme: baseline to 2 months after last dose
|
baseline to 2 months after last dose
|
Compare the effect of these treatment regimens on potential surrogate end-point biomarkers in areas of actinic keratosis, sun-exposed skin, and non-sun-exposed skin and correlate these biomarkers with clinical outcome in these patients.
Tidsramme: baseline to 2 months after last dose
|
baseline to 2 months after last dose
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Craig A. Elmets, MD, University of Alabama at Birmingham
Publikationer og nyttige links
Generelle publikationer
- Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.
- Bakshi A, Shafi R, Nelson J, Cantrell WC, Subhadarshani S, Andea A, Athar M, Elmets CA. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Br J Dermatol. 2020 Apr;182(4):995-1002. doi: 10.1111/bjd.18338. Epub 2019 Sep 11.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Neoplasmer
- Keratose, aktinisk
- Keratose
- Forstadier til kræft
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Cyclooxygenase-hæmmere
- Cyclooxygenase 2-hæmmere
- Celecoxib
Andre undersøgelses-id-numre
- CDR0000069099
- UAB-9833
- UAB-NQ401A4009
- UAB-NQ49902009
- NCI-P00-0161
- NCI-P01-0197
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AfsluttetSund og rask | Kropssammensætning